Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2.74% is 37% above its 5-year average of -4.33%, near the high end of its 5-year range (-59.61%–16.65%).
3.08% above its 12-month average of -2.83%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1.74%.
EBITDA MARGIN
-2.74%
EBITDA MARGIN AVG TTM
-2.83%
EBITDA MARGIN AVG 3Y
-4.80%
EBITDA MARGIN AVG 5Y
-4.33%
EBITDA MARGIN AVG 10Y
4.24%
EBITDA MARGIN AVG 15Y
7.98%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+3.08%
CURRENT VS 3Y AVG
+42.88%
CURRENT VS 5Y AVG
+36.72%
CURRENT VS 10Y AVG
-164.61%
CURRENT VS 15Y AVG
-134.34%
CURRENT VS 20Y AVG
N/A
Market Cap
$160.80M
EBITDA Margin
-3676.90%
TTM Avg
-2033.97%
3Y Avg
-1569.70%
5Y Avg
-1569.70%
Market Cap
$156.62M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$155.62M
EBITDA Margin
-48812.58%
TTM Avg
-48812.58%
3Y Avg
-48812.58%
5Y Avg
-48812.58%
Market Cap
$154.76M
EBITDA Margin
-47.00%
TTM Avg
-68.63%
3Y Avg
-61.93%
5Y Avg
-48.63%
Market Cap
$165.46M
EBITDA Margin
-416.41%
TTM Avg
-228.13%
3Y Avg
-163.44%
5Y Avg
-116.60%
Market Cap
$153.56M
EBITDA Margin
-0.19%
TTM Avg
-1.66%
3Y Avg
-11.02%
5Y Avg
-42.72%
Market Cap
$148.07M
EBITDA Margin
-550.97%
TTM Avg
-275.49%
3Y Avg
-275.49%
5Y Avg
-275.49%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inogen, Inc. (INGN) | $159.74M | -2.74% | -2.83% | -4.80% | -4.33% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $160.80M | -3676.90% | -2033.97% | -1569.70% | -1569.70% |
| Anavex Life Sciences Corp. (AVXL)vs › | $158.01M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $156.62M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $155.62M | -48812.58% | -48812.58% | -48812.58% | -48812.58% |
| Codexis, Inc. (CDXS)vs › | $154.76M | -47.00% | -68.63% | -61.93% | -48.63% |
| Coherus Oncology, Inc. (CHRS)vs › | $165.46M | -416.41% | -228.13% | -163.44% | -116.60% |
| LifeMD, Inc. (LFMDP)vs › | $153.56M | -0.19% | -1.66% | -11.02% | -42.72% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $148.07M | -550.97% | -275.49% | -275.49% | -275.49% |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.95M | -239.78% | -210.59% | -2213.91% | -2345.87% |
Gross Margin
48.9%
EBITDA Margin
-2.7%
Operating Margin
-8.4%
Net Margin
-6.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1.74% |
| 2026-03-31 | -4.13% |
| 2025-12-31 | -5.23% |
| 2025-09-30 | -2.05% |
| 2025-06-30 | -0.99% |
| 2025-03-31 | -3.00% |
| 2024-12-31 | -7.87% |
| 2024-09-30 | -2.79% |
| 2024-06-30 | -1.94% |
| 2024-03-31 | -14.11% |
| 2023-12-31 | -31.41% |
| 2023-09-30 | -50.15% |
| 2023-06-30 | -8.92% |
| 2023-03-31 | -24.71% |
| 2022-12-31 | -59.61% |
| 2022-09-30 | -4.14% |
| 2022-06-30 | 2.87% |
| 2022-03-31 | -9.74% |
| 2021-12-31 | -1.19% |
| 2021-09-30 | 12.78% |
| 2021-06-30 | 16.65% |
| 2021-03-31 | 3.41% |
| 2020-12-31 | -0.80% |
| 2020-09-30 | 3.68% |
| 2020-06-30 | 2.97% |
| 2020-03-31 | 2.58% |
| 2019-12-31 | -0.89% |
| 2019-09-30 | 12.83% |
| 2019-06-30 | 14.75% |
| 2019-03-31 | 8.48% |
| 2018-12-31 | 8.72% |
| 2018-09-30 | 13.76% |
| 2018-06-30 | 17.32% |
| 2018-03-31 | 14.79% |
| 2017-12-31 | 12.91% |
| 2017-09-30 | 16.32% |
| 2017-06-30 | 18.11% |
| 2017-03-31 | 16.71% |
| 2016-12-31 | 18.56% |
| 2016-09-30 | 16.19% |
| 2016-06-30 | 20.97% |
| 2016-03-31 | 15.64% |
| 2015-12-31 | 17.35% |
| 2015-09-30 | 17.84% |
| 2015-06-30 | 20.01% |
| 2015-03-31 | 17.66% |
| 2014-12-31 | 16.25% |
| 2014-09-30 | 23.00% |
| 2014-06-30 | 22.67% |
| 2014-03-31 | 17.80% |
| 2013-12-31 | 15.70% |
| 2013-09-30 | 16.32% |
| 2013-06-30 | 21.75% |
| 2013-03-31 | 14.57% |
| 2012-12-31 | 12.55% |
| 2012-09-30 | 12.55% |
